Rational use of polymyxin B in patients with multiple drug-resistant bacterial infections: a multicenter prospective real world study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200064300

Enrollment

Unknown

Registered

2022-10-02

Start date

2022-10-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection of multidrug resistant bacteria

Interventions

Intravenous group:Polymyxin B was administered intravenously

Intravenous combined inhalation group: Polymyxin B was administered intravenously combinated with atomization inhalation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age >= 18 2. Other antibiotic treatments were ineffective 3. Application of polymyxin B >= 5 times 4. Sign informed consent

Exclusion criteria

Exclusion criteria: 1. Previous history of asthma 2. Allergic history of polymyxin 3. Excessive colistin B was applied within 7 days before enrollment 4. Creatinine clearance rate <30ml/min

Design outcomes

Primary

Measure	Time frame
mortality;	—

Secondary

Measure	Time frame
improvement;cure;failure;clear;replacement;not clear;	—

Countries

China

Contacts

Public ContactChu Yufeng

The Second Hospital, Cheeloo College of Medicine, Shandong University

chunancy@163.com+86 17660083632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026